Cantor Fitzgerald Research Analysts Lower Earnings Estimates for Lucid Diagnostics Inc. (NASDAQ:LUCD)

Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) – Stock analysts at Cantor Fitzgerald reduced their FY2023 earnings per share estimates for shares of Lucid Diagnostics in a research report issued on Wednesday, May 17th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($1.32) per share for the year, down from their prior estimate of ($1.19). The consensus estimate for Lucid Diagnostics’ current full-year earnings is ($1.32) per share.

Separately, Needham & Company LLC restated a “buy” rating and issued a $2.60 target price on shares of Lucid Diagnostics in a report on Friday, April 21st.

Lucid Diagnostics Price Performance

LUCD opened at $1.58 on Monday. The stock has a fifty day moving average of $1.48 and a 200-day moving average of $1.52. The firm has a market capitalization of $68.56 million, a P/E ratio of -1.06 and a beta of 2.04. Lucid Diagnostics has a 12-month low of $1.11 and a 12-month high of $3.64.

Lucid Diagnostics (NASDAQ:LUCD – Get Rating) last released its earnings results on Tuesday, March 14th. The company reported ($0.29) earnings per share (EPS) for the quarter. The firm had revenue of $0.11 million during the quarter.

Institutional Trading of Lucid Diagnostics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Lucid Diagnostics by 25.6% during the first quarter. Vanguard Group Inc. now owns 312,876 shares of the company’s stock worth $1,051,000 after acquiring an additional 63,687 shares in the last quarter. BlackRock Inc. grew its position in Lucid Diagnostics by 18.7% in the first quarter. BlackRock Inc. now owns 67,565 shares of the company’s stock worth $227,000 after acquiring an additional 10,636 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Lucid Diagnostics during the 1st quarter worth $209,000. State Street Corp increased its stake in shares of Lucid Diagnostics by 24.4% during the 1st quarter. State Street Corp now owns 56,693 shares of the company’s stock worth $190,000 after purchasing an additional 11,121 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Lucid Diagnostics during the 1st quarter valued at $122,000. 5.89% of the stock is currently owned by hedge funds and other institutional investors.

About Lucid Diagnostics

(Get Rating)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.